Search Results - "Dumbrava, Ecaterina E"

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer by Meric-Bernstam, Funda, Johnson, Amber M, Dumbrava, Ecaterina E Ileana, Raghav, Kanwal, Balaji, Kavitha, Bhatt, Michelle, Murthy, Rashmi K, Rodon, Jordi, Piha-Paul, Sarina A

“…The introduction of HER2-targeted therapy for breast and gastric patients with ( ) amplification/overexpression has led to dramatic improvements in oncologic…”
Get full text

Precision Oncology Decision Support: Current Approaches and Strategies for the Future by Kurnit, Katherine C, Dumbrava, Ecaterina E Ileana, Litzenburger, Beate, Khotskaya, Yekaterina B, Johnson, Amber M, Yap, Timothy A, Rodon, Jordi, Zeng, Jia, Shufean, Md Abu, Bailey, Ann M, Sánchez, Nora S, Holla, Vijaykumar, Mendelsohn, John, Shaw, Kenna Mills, Bernstam, Elmer V, Mills, Gordon B, Meric-Bernstam, Funda

“…With the increasing availability of genomics, routine analysis of advanced cancers is now feasible. Treatment selection is frequently guided by the molecular…”
Get full text

A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies by Hegde, Aparna, Jayaprakash, Priyamvada, Couillault, Coline A, Piha-Paul, Sarina, Karp, Daniel, Rodon, Jordi, Pant, Shubham, Fu, Siqing, Dumbrava, Ecaterina E, Yap, Timothy A, Subbiah, Vivek, Bhosale, Priya, Coarfa, Cristian, Higgins, Jack P, Williams, Eric T, Wilson, Thomas F, Lim, JoAnn, Meric-Bernstam, Funda, Sumner, Elizabeth, Zain, Hira, Nguyen, Di, Nguyen, Ly M, Rajapakshe, Kimal, Curran, Michael A, Hong, David S

“…As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates…”
Get full text

Phase 2 study of pembrolizumab in patients with advanced rare cancers by Naing, Aung, Meric-Bernstam, Funda, Stephen, Bettzy, Karp, Daniel D, Hajjar, Joud, Rodon Ahnert, Jordi, Piha-Paul, Sarina A, Colen, Rivka R, Jimenez, Camilo, Raghav, Kanwal P, Ferrarotto, Renata, Tu, Shi-Ming, Campbell, Matthew, Wang, Linghua, Sabir, Sarjeel H, Tapia, Coya, Bernatchez, Chantale, Frumovitz, Michael, Tannir, Nizar, Ravi, Vinod, Khan, Saria, Painter, Jeane M, Abonofal, Abulrahman, Gong, Jing, Alshawa, Anas, McQuinn, Lacey M, Xu, Mingxuan, Ahmed, Sara, Subbiah, Vivek, Hong, David S, Pant, Shubham, Yap, Timothy A, Tsimberidou, Apostolia M, Dumbrava, Ecaterina E Ileana, Janku, Filip, Fu, Siqing, Simon, Richard M, Hess, Kenneth R, Varadhachary, Gauri R, Amir Habra, Mouhammed

“…Patients with advanced rare cancers have poor prognosis and few treatment options. As immunotherapy is effective across multiple cancer types, we aimed to…”
Get full text

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan by Zhao, Ming, DiPeri, Timothy P., Raso, Maria Gabriela, Zheng, Xiaofeng, Rizvi, Yasmeen Qamar, Evans, Kurt W., Yang, Fei, Akcakanat, Argun, Roberto Estecio, Marco, Tripathy, Debu, Dumbrava, Ecaterina E., Damodaran, Senthil, Meric-Bernstam, Funda

“…TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2…”
Get full text

Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies by Chang, Joe Y, Xu, Xinyan, Shroff, Girish S, Comeaux, Nathan I, Li, Wei, Rodon Ahnert, Jordi, Karp, Daniel D, Dumbrava, Ecaterina E, Verma, Vivek, Chen, Aileen, Welsh, James, Hong, David S

“…BackgroundBMS-986156 is an agonist of the glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR) and promotes increased effector…”
Get full text

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors by Hong, David S, Butler, Marcus O, Pachynski, Russell K, Sullivan, Ryan, Kebriaei, Partow, Boross-Harmer, Sarah, Ghobadi, Armin, Frigault, Matthew J, Dumbrava, Ecaterina E, Sauer, Amy, Brophy, Francine, Navenot, Jean-Marc, Fayngerts, Svetlana, Wolchinsky, Zohar, Broad, Robyn, Batrakou, Dzmitry G, Wang, Ruoxi, Solis, Luisa M, Duose, Dzifa Yawa, Sanderson, Joseph P, Gerry, Andrew B, Marks, Diane, Bai, Jane, Norry, Elliot, Fracasso, Paula M

“…ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T-cells are genetically engineered autologous T-cells that express a high-affinity…”
Get full text

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences by Yao, Shuyang, Meric-Bernstam, Funda, Hong, David, Janku, Filip, Naing, Aung, Piha-Paul, Sarina Anne, Tsimberidou, Apostolia Maria, Karp, Daniel, Subbiah, Vivek, Yap, Timothy Anthony, Ahnert, Jordi Rodon, Pant, Shubham, Dumbrava, Ecaterina E Ileana, Wathoo, Chetna, Campbell, Erick, Yu, Lihou, Yamamura, Yuko, Fu, Siqing

“…Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying…”
Get full text

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer by Son, Ji, Lin, Heather Y, Fu, Siqing, Biter, Amadeo B, Dumbrava, Ecaterina E, Karp, Daniel D, Naing, Aung, Pant, Shubham, Piha-Paul, Sarina A, Rodon, Jordi, Subbiah, Vivek, Tsimberidou, Apostolia M, Yap, Timothy A, Frumovitz, Michael M, Jazaeri, Amir A, Ramirez, Pedro T, Westin, Shannon N, Yuan, Ying, Meric-Bernstam, Funda, Hong, David S

“…We aimed to identify clinical, pathologic, and treatment factors that are predictive of response and survival in patients with cervical cancer referred to…”
Get full text

Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing by Nowlen, Carol J, Daniels, Molly, Uzunparmak, Burak, Ileana Dumbrava, Ecaterina E, Yuan, Ying, Patel, Keyur P, Rayes, Nadine, Harkenrider, Jacqueline, Wathoo, Chetna, Veazie, Jennifer, Luna, Krystle A, Wang, Wanlin, Horombe, Chacha, Javle, Milind, Ahnert, Jordi Rodon, Yap, Timothy A, Arun, Banu, Lu, Karen H, Meric-Bernstam, Funda

“…Genomic profiling is performed in patients with advanced or metastatic cancer, in order to direct cancer treatment, often sequencing tumor-only, without a…”
Get full text

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials by Yap, Timothy A., Daver, Naval, Mahendra, Mikhila, Zhang, Jixiang, Kamiya-Matsuoka, Carlos, Meric-Bernstam, Funda, Kantarjian, Hagop M., Ravandi, Farhad, Collins, Meghan E., Francesco, Maria Emilia Di, Dumbrava, Ecaterina E., Fu, Siqing, Gao, Sisi, Gay, Jason P., Gera, Sonal, Han, Jing, Hong, David S., Jabbour, Elias J., Ju, Zhenlin, Karp, Daniel D., Lodi, Alessia, Molina, Jennifer R., Baran, Natalia, Naing, Aung, Ohanian, Maro, Pant, Shubham, Pemmaraju, Naveen, Bose, Prithviraj, Piha-Paul, Sarina A., Rodon, Jordi, Salguero, Carolina, Sasaki, Koji, Singh, Anand K., Subbiah, Vivek, Tsimberidou, Apostolia M., Xu, Quanyun A., Yilmaz, Musa, Zhang, Qi, Li, Yuan, Bristow, Christopher A., Bhattacharjee, Meenakshi B., Tiziani, Stefano, Heffernan, Timothy P., Vellano, Christopher P., Jones, Philip, Heijnen, Cobi J., Kavelaars, Annemieke, Marszalek, Joseph R., Konopleva, Marina

“…Although targeting oxidative phosphorylation (OXPHOS) is a rational anticancer strategy, clinical benefit with OXPHOS inhibitors has yet to be achieved. Here…”
Get full text

Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets by Sofianidi, Amalia, Dumbrava, Ecaterina E, Syrigos, Konstantinos N, Nasrazadani, Azadeh

“…Worldwide, breast cancer is the most frequently diagnosed malignancy in women, with triple-negative breast cancer (TNBC) being the most aggressive molecular…”
Get full text

Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer by Santin, Alessandro D, Corr, Bradley R, Spira, Alexander, Willmott, Lyndsay, Butrynski, James, Tse, Ka Yu, Patel, Jilpa, Mekan, Sabeen, Wu, Tia, Lin, Kai-Wen, Kuo, Peiwen, Dumbrava, Ecaterina E

“…Patients with advanced endometrial cancer (EC) who progress on or after platinum-based therapy and immunotherapy have poor prognosis. We report efficacy and…”
Get full text

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification by Fu, Siqing, Yao, Shuyang, Yuan, Yuan, Previs, Rebecca A, Elias, Anthony D, Carvajal, Richard D, George, Thomas J, Yuan, Ying, Yu, Lihou, Westin, Shannon N, Xing, Yan, Dumbrava, Ecaterina E, Karp, Daniel D, Piha-Paul, Sarina A, Tsimberidou, Apostolia M, Ahnert, Jordi Rodon, Takebe, Naoko, Lu, Karen, Keyomarsi, Khandan, Meric-Bernstam, Funda

“…Preclinical cancer models harboring amplification were more sensitive to adavosertib treatment, a WEE1 kinase inhibitor, than models without amplification…”
Get full text

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers by DiPeri, Timothy P, Evans, Kurt W, Raso, Maria Gabriela, Zhao, Ming, Rizvi, Yasmeen Q, Zheng, Xiaofeng, Wang, Bailiang, Kirby, Bryce P, Kong, Kathleen, Kahle, Michael, Yap, Timothy A, Dumbrava, Ecaterina E, Ajani, Jaffer A, Fu, Siqing, Keyomarsi, Khandan, Meric-Bernstam, Funda

“…Cyclin E (CCNE1) has been proposed as a biomarker of sensitivity to adavosertib, a Wee1 kinase inhibitor, and a mechanism of resistance to HER2-targeted…”
Get full text

Discordance of HER2 Expression and/or Amplification on Repeat Testing by DiPeri, Timothy P, Kong, Kathleen, Varadarajan, Kaushik, Karp, Daniel D, Ajani, Jaffer A, Pant, Shubham, Press, Michael F, Piha-Paul, Sarina A, Dumbrava, Ecaterina E, Meric-Bernstam, Funda

“…We sought to assess discordance of HER2 status in patients with HER2-amplified/expressing solid tumors who underwent reevaluation of HER2 status. Patients with…”
Get full text

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies by Knisely, Anne, Ahmed, Jibran, Stephen, Bettzy, Piha‐Paul, Sarina A., Karp, Daniel, Zarifa, Abdulrazzak, Fu, Siqing, Hong, David Sanghyun, Rodon Ahnert, Jordi, Yap, Timothy A., Tsimberidou, Apostolia M., Alshawa, Anas, Dumbrava, Ecaterina E., Yang, Yali, Song, Juhee, Meric‐Bernstam, Funda, Jazaeri, Amir A., Naing, Aung

“…Background Immune checkpoint blockade has shown mixed results in advanced/recurrent gynecologic malignancies. Efficacy may be improved through costimulation…”
Get full text

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors by Piha-Paul, Sarina A, Xu, Binghe, Dumbrava, Ecaterina E, Fu, Siqing, Karp, Daniel D, Meric-Bernstam, Funda, Hong, David S, Rodon, Jordi A, Tsimberidou, Apostolia M, Raghav, Kanwal, Ajani, Jaffer A, Conley, Anthony P, Mott, Frank, Fan, Ying, Fan, Jean, Peng, Peng, Wang, Hui, Ni, Shumao, Sun, Caixia, Qiang, Xiaoyan, Levin, Wendy J, Ngo, Brenda, Ru, Qinhua Cindy, Wu, Frank, Javle, Milind M

“…This first-in-human phase I dose-escalation study evaluated the safety, pharmacokinetics, and efficacy of tinengotinib (TT-00420), a multi-kinase inhibitor…”
Get full text

Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts by DiPeri, Timothy P, Evans, Kurt W, Wang, Bailiang, Zhao, Ming, Akcakanat, Argun, Raso, Maria Gabriela, Rizvi, Yasmeen Q, Zheng, Xiaofeng, Korkut, Anil, Varadarajan, Kaushik, Uzunparmak, Burak, Dumbrava, Ecaterina E, Pant, Shubham, Ajani, Jaffer A, Pohlmann, Paula R, Jensen, V Behrana, Javle, Milind, Rodon, Jordi, Meric-Bernstam, Funda

“…Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in a broad range of…”
Get more information

Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience by D. Barber, PhD, ANP-BC, AOCNP, FAANP, FAAN, Fedricker, Campbell, MS, Erick, Yamamura, BA, Yuko, J. Patterson, DNP, MPH, WHNP, ANP, Clover, C. Hartnett, MSN, NP-C, Audrey, Kinahan, MSN, ANP-C, AOCNP, Holly, A. Miller, MSN, FNP-BC, Victoria, L. Brink, DNP, FNP-BC, AOCNP, Amanda, Poullard, DNP, ACNP-BC, Anna, E. Urshel, DNP, FNP-BC, Gabriele, Brantley, MSN, AGNP-C, Andre, G. Cepeda, MSN, AGNP-C, Isabel, Goswami, DNP, FNP-C, AOCNP, Poonam, Charles, MSN, FNP-BC, Sheena, Philip, MSN, FNP, Shincy, Bresser, MPAS, PA-C, Sara, Musekiwa-Adjei, MSN, FNP-C, Sandra, Perez, MSN, FNP-C, Nageli, Le, PhD, Hung, Phillips, RN, MSN, MBA, Penny, Subbiah, MD, Vivek, Meric-Bernstam, MD, Funda, E. Dumbrava, MD, Ecaterina

“…Background: Advanced practice providers (APPs) play important roles in enrolling, educating, and caring for patients in clinical trials. However, much remains…”
Get full text